INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCC

🌐 OncLive —
INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCC

AI Summary

A study revealed that combining INBRX-106 with Pembrolizumab provides a significant advantage compared to Pembrolizumab alone for first-line HNSCC treatment. The implications for treatment protocols may be substantial.

Markets Health INBRX-106 Pembrolizumab HNSCC cancer treatment clinical trial efficacy

Read original source →